Bristol Myers Squibb (BMY) EBITDA Margin (2009 - 2026)

Bristol Myers Squibb has disclosed EBITDA Margin across 18 years of filings, most recently posting 24.65% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 437.0% year-over-year to 24.65%; the TTM figure through Mar 2026 stood at 15.12% (up 379.0% YoY), while the FY2025 annual figure was 14.04%, up 3193.0% from the prior year.
• EBITDA Margin climbed to 24.65% in Q1 2026, from 8.6% in the prior quarter.
• Over the last five years, EBITDA Margin for BMY reached as high as 24.65% in Q1 2026 and fell as low as 99.16% in Q1 2024.
• The 5-year median for EBITDA Margin is 13.87% (2022), against an average of 7.77%.
• Annual changes were most pronounced in 2024 — EBITDA Margin plunged 11834 bps — and 2025, when it jumped 11943 bps.
• A 5-year view of EBITDA Margin shows it stood at 13.87% in 2022, then fell by 6 bps to 13.09% in 2023, then tumbled by 81 bps to 2.45% in 2024, then surged by 251 bps to 8.6% in 2025, then jumped by 187 bps to 24.65% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 24.65%, 8.6%, and 18.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.